Transcatheter Aortic Valve Implantation: Other Devices

Supported by favorable data from first-generation devices, TAVI has undergone rapid technological advancements. The focus on these innovations was on limiting complications found with early TAVI devices such as paravalvular regurgitation, conduction disturbances, valve malpositioning, and the impossibility of repositioning and retrieving the prosthesis. Innovations were achieved both on device designs and on delivery system technologies. Some second-generation devices have already received the CE Mark (Sapien 3, Edwards Lifesciences; CoreValve Evolut R, Medtronic; Portico™, St. Jude Medical, St. Paul, MN, USA; ACURATE neo™, Symetis, Ecublens, Switzerland; Lotus™, Boston Scientific, Marlborough, MA, USA), while other devices are in early clinical evaluation but have yet to receive the CE Mark.